Gilead Sciences Inc. and GlaxoSmithKline plc are among suitors weighing bids for United Therapeutics Corp., the Evening Standard reported Aug. 4, citing anonymous sources.

The news outlet reported that Gilead is most likely to win a bid, while Novartis AG is another possible contender. According to the anonymous sources, United could be worth as much as $200 per share in a sale, making the purchase price around $8.7 billion.

GSK is being advised by Lazard and Citi in the process, the Evening Standard reported.